journal article·2022-09

Crystal structure of merimepodib, C 23 H 24 N 4 O 6

James A. Kaduk, Stacy Gates-Rector, Amy M. Gindhart, Thomas N. Blanton

Powder Diffraction· Volume 37· Issue 3
Publisher page

Abstract

The crystal structure of merimepodib has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Merimepodib crystallizes in space group P 2 1 2 1 2 1 (#19) with a = 4.60827(3), b = 12.30400(14), c = 37.9583(4) Å, V = 2152.241(20) Å 3 , and Z = 4. The crystal structure is dominated by two chains of N–H⋯O hydrogen bonds along the a -axis. The solid-state conformation has a similar general shape to the minimum-energy conformation, but different orientations of several of the rings. The differences indicate that intermolecular interactions are important in determining the solid-state conformation. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF ® ).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Thermal and Kinetic Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (38)

Show source-provided references
1. 2021
2. 10.1017/S088571561400090610.1017/S0885715614000906 ↗
3. 10.1002/anie.19951555110.1002/anie.199515551 ↗
4. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
5. Armistead, D. M. , Badia, M. C. , Bemis, G. W. , Bethiel, R. S. , Fank, C. A. , Novak, P. M. , Ronkin, S. M. , and Saunders, J. O. (2000). “Inhibitors of IMPDH enzyme,” US Patent 6,054,472.
6. 10.1093/nar/gky103310.1093/nar/gky1033 ↗
7. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
8. Etudes sur la loi de bravais
9. 2020
10. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
11. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
12. 10.1021/ci049780b10.1021/ci049780b ↗
13. 10.1186/1758-2946-3-3310.1186/1758-2946-3-33 ↗
14. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
15. Armistead, D. M. , Badia, M. C. , Bemis, G. W. , Bethiel, R. S. , Fank, C. A. , Novak, P. M. , Ronkin, S. M. , and Saunders, J. O. (1997). “Urea derivatives as inhibitors of IMPDH enzyme,” International Patent Application WO 97/40028.
16. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
17. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
18. Armistead, D. M. , Badia, M. C. , Bemis, G. W. , Bethiel, R. S. , Fank, C. A. , Novak, P. M. , Ronkin, S. M. , and Saunders, J. O. (1998). “Inhibitors of IMPDH enzyme,” US Patent 5,807,876.
19. A new law of crystal morphology extending the law of Bravais
20. 2016
21. 10.1063/1.46788210.1063/1.467882 ↗
22. BioSig (2020). https://ir.biosig.com/press-releases/detail/234/viralclear-halts-its-phase-2-hospitalized-covid-19-trial (accessed January 20, 2020).
23. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
24. 10.1107/S002188980201523610.1107/S0021889802015236 ↗
25. 10.1021/op800060h10.1021/op800060h ↗
26. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
27. Bravais · 1866
28. 10.1002/1520-6017(200105)90:5<625::AID-JPS1019>3.0.CO;2-110.1002/1520-6017(200105)90:5<625::AID-JPS1019>3.0.CO;2-1 ↗
29. Turner · 2017
30. 10.1007/BF0054909610.1007/BF00549096 ↗
31. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
32. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
33. 10.1063/1.296926010.1063/1.2969260 ↗
34. Crystal Impact - Dr. H. Putz & Dr. K. Brandenburg (2021). Diamond - Crystal and Molecular Structure Visualization (Kreuzherrenstr. 102, 53227 Bonn, Germany). Available at: https://www.crystalimpact.de/diamond.
35. 10.1021/ar00172a00510.1021/ar00172a005 ↗
36. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
37. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
38. Quantum-mechanical condensed matter simulations with CRYSTAL